Market Insights Health Hospitals Inpatient Care

Neoplasm Treatment - Nordics

Nordics

The Neoplasm Treatment market in the Nordics is expected to witness a significant growth in revenue, projected to reach US$4.24bn in 2024.
This market is estimated to exhibit an annual growth rate of 3.27% from 2024 to 2029, leading to a market volume of US$4.98bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, with an estimated value of US$90.56bn in 2024.
In the Nordics, the neoplasm treatment market is witnessing a surge in the adoption of innovative immunotherapies.

Key regions: Europe, Canada, Brazil, United States, United Kingdom

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.